RNA, U2 small nuclear 19, pseudogene (RNU2-19P)

RNU2-19P (RNA, U2 small nuclear 19, pseudogene) is classified as a pseudogene of the U2 small nuclear RNA (snRNA) family in the human genome. Pseudogenes are genomic DNA sequences similar to normal genes but typically are non-functional due to mutations, deletions, or truncations that prevent them from producing functional RNA or proteins. U2 snRNA itself is a component of the spliceosome, playing a central role in pre-mRNA splicing by recognizing the branch site of introns and facilitating removal during splicing[1][2][3][4]. However, RNU2-19P, by definition as a pseudogene, does not produce functional U2 snRNA and therefore is not involved in any known specific biological functions or disease processes and is not a therapeutic target. There are no known drugs, mechanisms of action, biomarker roles, or therapeutic safety concerns associated with RNU2-19P. The entry is potentially incorrect or misleading as a drug/discovery/therapeutic target for several reasons: - It is a pseudogene, not a protein-coding gene, receptor, enzyme, transporter, or functional noncoding RNA. - Functional U2 snRNA genes (e.g., RNU2-1, RNU2-2) are important in splicing, but pseudogenes like RNU2-19P generally do not produce functional RNA and are not involved in cellular processes targeted by therapeutics[2][3]. In summary, RNU2-19P should not be considered a therapeutic target or associated with drugs, mechanisms of action, disease roles, biomarkers, or safety concerns. The canonical and scientific use of this name refers to an inactive genomic locus with sequence similarity to the functional U2 snRNA genes.

Other names

RNU2-19P